- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Apogee Technology, Inc. (AMEX: ATA), a nanotechnology and micro-electrical mechanical systems company that designs, develops and commercializes drug delivery and sensor systems, previously issued its Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 and is amending the 10-KSB to include, among other items, the Part III information regarding management and its compensation. Apogee is currently in the process of scheduling its 2007 Annual Meeting and preparing its Proxy and Notice to Stockholders. In compliance with the AMEX Company Guide Rule 610(b), the Company is disclosing that its previously issued audit report for the fiscal year ended December 31, 2006, contains a going concern qualification. There is no change or amendment to the financial statements as originally filed.
About Apogee Technology, Inc.
Apogee Technology designs, develops and commercializes proprietary medical device and sensor products using its micro-electrical mechanical systems ("MEMS") and nanotechnology for the medical, automotive, industrial and consumer markets. The Company is developing its PyraDerm™ solution for enhanced intradermal drug delivery and has introduced a family of pressure sensors under the Sensilica® brand. Apogee's goal is to provide value-added and cost-saving solutions for our customers and, in so doing, become a global leader in the sensor and medical device fields. For more information please visit our web site at: http://www.apogeemems.com .
PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders. Certain statements made herein that use the words "anticipate," "may,""hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve the design, development and production efforts of our PyraDerm™ and Sensilica® technologies, known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.
For more information, please click here
Apogee Investor Contact:
Premier Funding & Financial Marketing
Copyright © Market WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
Strength of hair inspires new materials for body armor January 18th, 2017
Self-assembling particles brighten future of LED lighting January 18th, 2017
Nanoparticle exposure can awaken dormant viruses in the lungs January 17th, 2017
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016